The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer - PubMed (original) (raw)

The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer

J Kleeff et al. J Clin Invest. 1998.

Abstract

Heparan sulfate proteoglycans (HSPGs) play diverse roles in cell recognition, growth, and adhesion. In vitro studies suggest that cell-surface HSPGs act as coreceptors for heparin-binding mitogenic growth factors. Here we show that the glycosylphosphatidylinositol- (GPI-) anchored HSPG glypican-1 is strongly expressed in human pancreatic cancer, both by the cancer cells and the adjacent fibroblasts, whereas expression of glypican-1 is low in the normal pancreas and in chronic pancreatitis. Treatment of two pancreatic cancer cell lines, which express glypican-1, with the enzyme phosphoinositide-specific phospholipase-C (PI-PLC) abrogated their mitogenic responses to two heparin-binding growth factors that are commonly overexpressed in pancreatic cancer: fibroblast growth factor 2 (FGF2) and heparin-binding EGF-like growth factor (HB-EGF). PI-PLC did not alter the response to the non-heparin-binding growth factors EGF and IGF-1. Stable expression of a form of glypican-1 engineered to possess a transmembrane domain instead of a GPI anchor conferred resistance to the inhibitory effects of PI-PLC on growth factor responsiveness. Furthermore, transfection of a glypican-1 antisense construct attenuated glypican-1 protein levels and the mitogenic response to FGF2 and HB-EGF. We propose that glypican-1 plays an essential role in the responses of pancreatic cancer cells to certain mitogenic stimuli, that it is relatively unique in relation to other HSPGs, and that its expression by pancreatic cancer cells may be of importance in the pathobiology of this disorder.

PubMed Disclaimer

Similar articles

• Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells.
  Kleeff J, Wildi S, Kumbasar A, Friess H, Lander AD, Korc M. Kleeff J, et al. Pancreas. 1999 Oct;19(3):281-8. doi: 10.1097/00006676-199910000-00009. Pancreas. 1999. PMID: 10505759
• Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells.
  Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Matsuda K, et al. Cancer Res. 2001 Jul 15;61(14):5562-9. Cancer Res. 2001. PMID: 11454708
• Growth factor-induced shedding of syndecan-1 confers glypican-1 dependence on mitogenic responses of cancer cells.
  Ding K, Lopez-Burks M, Sánchez-Duran JA, Korc M, Lander AD. Ding K, et al. J Cell Biol. 2005 Nov 21;171(4):729-38. doi: 10.1083/jcb.200508010. Epub 2005 Nov 14. J Cell Biol. 2005. PMID: 16286510 Free PMC article.
• Heparin-binding EGF-like growth factor.
  Raab G, Klagsbrun M. Raab G, et al. Biochim Biophys Acta. 1997 Dec 9;1333(3):F179-99. doi: 10.1016/s0304-419x(97)00024-3. Biochim Biophys Acta. 1997. PMID: 9426203 Review.
• Tenascin-C: Form versus function.
  Giblin SP, Midwood KS. Giblin SP, et al. Cell Adh Migr. 2015;9(1-2):48-82. doi: 10.4161/19336918.2014.987587. Cell Adh Migr. 2015. PMID: 25482829 Free PMC article. Review.

Cited by

• Branched oncolytic peptides target HSPGs, inhibit metastasis, and trigger the release of molecular determinants of immunogenic cell death in pancreatic cancer.
  Rencinai A, Tollapi E, Marianantoni G, Brunetti J, Henriquez T, Pini A, Bracci L, Falciani C. Rencinai A, et al. Front Mol Biosci. 2024 Oct 2;11:1429163. doi: 10.3389/fmolb.2024.1429163. eCollection 2024. Front Mol Biosci. 2024. PMID: 39417004 Free PMC article.
• Upregulated Matrisomal Proteins and Extracellular Matrix Mechanosignaling Underlie Obesity-Associated Promotion of Pancreatic Ductal Adenocarcinoma.
  Waldron RT, Lugea A, Chang HH, Su HY, Quiros C, Lewis MS, Che M, Ramanujan VK, Rozengurt E, Eibl G, Pandol SJ. Waldron RT, et al. Cancers (Basel). 2024 Apr 21;16(8):1593. doi: 10.3390/cancers16081593. Cancers (Basel). 2024. PMID: 38672675 Free PMC article.
• Harnessing microRNA-enriched extracellular vesicles for liquid biopsy.
  Ko SY, Lee W, Naora H. Ko SY, et al. Front Mol Biosci. 2024 Feb 21;11:1356780. doi: 10.3389/fmolb.2024.1356780. eCollection 2024. Front Mol Biosci. 2024. PMID: 38449696 Free PMC article. Review.
• A Comprehensive Review of the Potential Role of Liquid Biopsy as a Diagnostic, Prognostic, and Predictive Biomarker in Pancreatic Ductal Adenocarcinoma.
  Stosic K, Senar OA, Tarfouss J, Bouchart C, Navez J, Van Laethem JL, Arsenijevic T. Stosic K, et al. Cells. 2023 Dec 19;13(1):3. doi: 10.3390/cells13010003. Cells. 2023. PMID: 38201207 Free PMC article. Review.
• Artificial intelligence-based analysis of time-lapse images of sphere formation and process of plate adhesion and spread of pancreatic cancer cells.
  Shichi Y, Gomi F, Hasegawa Y, Nonaka K, Shinji S, Takahashi K, Ishiwata T. Shichi Y, et al. Front Cell Dev Biol. 2023 Nov 17;11:1290753. doi: 10.3389/fcell.2023.1290753. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38046666 Free PMC article.

References

1. 1. Cell. 1991 Feb 22;64(4):841-8 - PubMed
2. 1. Int J Cancer. 1991 Jan 2;47(1):92-8 - PubMed
3. 1. Mol Cell Biol. 1992 Jan;12(1):240-7 - PubMed
4. 1. Hepatogastroenterology. 1991 Oct;38(5):408-12 - PubMed
5. 1. N Engl J Med. 1992 Feb 13;326(7):455-65 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • American Society for Clinical Investigation
  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal